3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
5
Terminated
3
Completed
3
Withdrawn
1
Unknown
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
13
Melanoma
11
Triple Negative Breast Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
8
Breast Neoplasms
8
Neoplasms
7
Head and Neck Neoplasms
7
Multiple Myeloma
6
Carcinoma, Transitional Cell
6
Carcinoma, Renal Cell
6
Pancreatic Neoplasms
5
Lung Neoplasms
4
Recurrence
3
Prostatic Neoplasms
3
Endometrial Neoplasms
3
Colorectal Neoplasms
3
Brain Neoplasms
3
Stomach Neoplasms
2
Sarcoma
2
Neoplasm Metastasis
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Kidney Neoplasms
2
Inflammatory Breast Neoplasms
2
Hematologic Neoplasms
2
Glioblastoma
2
Urothelial Cancer
1
Thyroid Neoplasms
1
Subcutaneous panniculitis-like T-cell lymphoma
1
Spinocerebellar Degenerations
1
Interventions
Paclitaxel
6
Radiotherapy
5
Carboplatin
5
capmatinib
2
Radiosurgery
2
Gemcitabine
2
tetrathiomolybdate
1
spartalizumab
1
pembrolizumab
1
palbociclib
1
onartuzumab
1
nintedanib
1
fludarabine phosphate
1
fludarabine
1
efaproxiral
1
durvalumab
1
binimetinib
1
aldesleukin
1
Vinorelbine
1
Technetium Tc 99m Sestamibi
1
Taxes
1
Sorafenib
1
Platinum
1
Nivolumab
1
Neoadjuvant Therapy
1
Magnetic Resonance Spectroscopy
1
Interleukin-2
1
Immunotherapy
1
Immunoenzyme Techniques
1
Gefitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Adenocarcinoma of Lung
×
pembrolizumab
×
Clear all
NCT05566223
2026-02-23
CheckCell-2
Intima Bioscience, Inc.
Phase 1/2
Withdrawn